USIL Therapeutics Passes NATO Vendor Registration Assessment
The Luxembourg biotech firm cleared an initial NATO Support and Procurement Agency vendor assessment, with final registration still pending.
Updated on Nov. 20, 2026 in Biotech

USIL Therapeutics, a Luxembourg-based biotechnology company, passed the initial vendor registration assessment of the NATO Support and Procurement Agency. The approval gives the company access to the NSPA procurement platform and the ability to take part in Request for Proposal processes.
Why it matters
Passing the initial assessment is an early step toward supplying NATO-linked procurement, but it does not guarantee any contracts. The company has not yet secured NATO procurement work and has not confirmed full registration.
The company is developing medical countermeasures for acute radiation syndrome and secured a €5.2m grant from the European Commission's EU4Health programme in May. Whether the final registration stage, which requires a Declaration of Eligibility from national authorities, will be completed has not been disclosed.
The players
USIL Therapeutics
A Luxembourg-based biotechnology company founded last year that is developing medical countermeasures for acute radiation syndrome.
NATO Support and Procurement Agency (NSPA)
The NATO agency responsible for procurement and support services for the alliance and its member nations, which operates the vendor registration platform.
The details
USIL Therapeutics, founded last year, is developing medical countermeasures for acute radiation syndrome. In July it announced a collaboration with Ariana Pharma on a mechanistic AI model for its UT-241 program.
Timeline
May: The company secured a €5.2m grant from the European Commission's EU4Health programme.
July: The company announced its collaboration with Ariana Pharma.
November 20: USIL Therapeutics passed the NSPA initial vendor registration assessment.
The Tech Race
The company's €5.2m EU4Health grant links its radiation countermeasure work to the EU's public health funding programme. Its NSPA assessment signals an attempt to move the same work into NATO defence procurement channels.
For most readers this news has no immediate effect, since the company has no NATO contracts yet. It matters mainly to those tracking how medical countermeasures for radiation exposure are funded and procured.
The takeaway
Passing an early vendor assessment is a step toward procurement eligibility rather than a sign of contract wins. Readers should watch for confirmation of full registration before treating the company as a NATO supplier.
What happens next
The final registration stage requires a Declaration of Eligibility from national authorities, though no date for that step has been set.
Further reading
Explore more Biotech coverage for context on how medical countermeasure developers are pursuing public and defence funding.
Source note: This article includes information reported by Manufacturingchemist.



